Parexel posts revenue increase in second quarter

Tuesday, January 31, 2012 02:23 PM

Boston-based CRO Parexel International posted a 9.5% increase in consolidated service revenue for the second quarter ended Dec. 31, 2011, to $333.2 million, from a year ago.

GAAP operating income for the quarter was $22.6 million, or 6.8% of consolidated service revenue (operating margin). GAAP net income totaled $12.9 million, or $0.21 per diluted share, compared with $16.8 million, or $0.28 per share, a year ago, a decrease of 23.1%. Excluding special items, adjusted operating income for the quarter was $23.8 million, or 7.1% operating margin, down 14% year-over-year.

Backlog at the end of December was approximately $3.74 billion, up 23.8% from a year ago.  The reported backlog included gross new business wins in the quarter of $622.2 million, cancellations of $121.7 million, a negative impact from foreign exchange rates of $29.7 million and a downward backlog adjustment of $3.8 million related to dispositions in the early phase business. The net book-to-bill ratio was 1.50 in the quarter.

“In the second quarter, we continued our positive momentum, demonstrating solid achievements in a number of key financial and operational areas,” said Josef H. von Rickenbach, Parexel’s chairman and CEO. “On a sequential basis, highlights included accelerated revenue growth for the company overall, an improved operating margin and earnings per share that were in line with our projections.  Our progress was broad-based, with each of our three reporting segments delivering higher gross margins on a sequential basis.  This was the result of improved operating leverage, further benefits of productivity and efficiency initiatives, and the impact of recent restructuring activities.”

Parexel issued forward-looking guidance for the third quarter of fiscal 2012 (ending March 31, 2012) and for fiscal 2012. It expects to report consolidated service revenue for the third quarter between $350 and $358 million, GAAP earnings per diluted share between $0.28 and $0.30 and adjusted earnings per diluted share between $0.30 and $0.32. For fiscal 2012, consolidated service revenue is expected between $1.360 and $1.375 billion, GAAP earnings per diluted share between $1.01 and $1.09, and adjusted earnings per diluted share between $1.09 and $1.17.  

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs